| Autor: |
dos Santos, Júlio César Claudino, Mano, Gabriela Braga Cabrera, da Cunha Barreto-Vianna, André Rodrigues, Garcia, Tulia Fernanda Meira, de Vasconcelos, Aline Vieira, Sá, Caio Sérgio Gomes, de Souza Santana, Sarah Lopes, Farias, Ana Gabriela Ponte, Seimaru, Beatriz, Lima, Micael Porto Portela, Goes, João Vitor Caetano, Gusmão, Camilla Teixeira Pinheiro, Junior, Howard Lopes Ribeiro |
| Zdroj: |
Molecular Neurobiology; Sep2024, Vol. 61 Issue 9, p6754-6770, 17p |
| Abstrakt: |
Parkinson's disease (PD) is a neurodegenerative disorder affecting 2–3% of those aged over 65, characterized by motor symptoms like slow movement, tremors, and muscle rigidity, along with non-motor symptoms such as anxiety and dementia. Lewy bodies, clumps of misfolded proteins, contribute to neuron loss in PD. Mutations in the GBA1 gene are considered the primary genetic risk factor of PD. GBA1 mutations result in decreased activity of the lysosomal enzyme glucocerebrosidase (GCase) resulting in α-synuclein accumulation. We know that α-synuclein aggregation, lysosomal dysfunction, and endoplasmic reticulum disturbance are recognized factors to PD susceptibility; however, the molecular mechanisms connecting GBA1 gene mutations to increased PD risk remain partly unknown. Thus, in this narrative review conducted according to a systematic review method, we aimed to present the main contributions arising from the molecular impact of the GBA1 gene to the pathogenesis of PD providing new insights into potential impacts for advances in the clinical care of people with PD, a neurological disorder that has contributed to the substantial increase in the global burden of disease accentuated by the aging population. In summary, this narrative review highlights the multifaceted impact of GBA1 mutations in PD, exploring their role in clinical manifestations, genetic predispositions, and molecular mechanisms. The review emphasizes the importance of GBA1 mutations in both motor and non-motor symptoms of PD, suggesting broader therapeutic and management strategies. It also discusses the potential of CRISPR/Cas9 technology in advancing PD treatment and the need for future research to integrate these diverse aspects for improved diagnostics and therapies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink